العلاج الجهازي لورم القواتم/ورم العقدة المجاورة للكبد النقيلي المتقدم مع المرض الممتص لـ MIBG

References

DOI: 10.1097/MPA.0000000000001792

• The use of MIBG therapy is indicated for patients with advanced mPPGL requiring systemic therapy and who have uptake in sites of disease on MIBG imaging.
• High specific activity ¹³¹I-MIBG should be considered for patients requiring systemic therapy and who have MIBG-avid disease (consensus).
• The only prospective registrational trial to date treated hypertensive mPPGL patients with high specific activity MIBG at 296 MBq/kg up to a maximum of 18.5 GBq (500 mCi) in each of 2 treatments 3 to 6 months apart.
• As for patients with mPPGL undergoing any systemic therapy, patients should have their BP well controlled before treatment and should be on α/β-blockade at time of treatment.